Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
The authors of the study conclude that "in this large European study, mPAC treatment choices seem overall in line with ESMO recommendations. However, substantial geographical variation was reported between countries. Apart from WHO performance status and comorbidities, first-line treatment choices followed local reimbursement status of individual compounds and showed country-specific preferences. Second-line treatment was also guided by first-line treatment. At the time this research was concluded, no second-line mPACtreatment was approved and over 20 treatment/combinations were reported. A more standardized approach may help to improve mPAC treatment outcomes."
Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): a quality of life randomized cross-over study (QOLINPAC)
Gabriela Chiritescu, et al., O-003
The authors of the study conclude that "median survival was long and response rate significantly higher in combination groups. Patients receiving the combination nab-paclitaxel/gemcitabine seem to report better QOL scores for a longer duration compared to patients on gemcitabine monotherapy. Further QOL analyses and translational studies are ongoing." (Financiel support & study medication: Celgene) EudraCT 2013-004101-75; NCT02106884.
Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (Mpdac) in the global NAPOLI-1 phase III trial
Teresa Macarulla Mercadé. et al., O-004
The authors of the study conclude that "in the NAPOLI-1 study, decreased appetite at baseline was shown to be prognostic for survival in patients with mPDAC who progressed after gemcitabine-based therapy. Thes results indicate that appropriate management is essential in patients with decreased appetite. We did not identify a significant prognostic effect of primary tumor localization, biliary stent, or best response to prior therapy in either the NAPOLI-1 ITT population or the nal-IRI+5FU/LV treatment arm on survival after trial inclusion. Nonetheless, a consistent treatment benefit was observed in patients treated with nal-IRI+5FU/LV vs. 5FU/LV alone across subgroups."